Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on enzymatic, non-surgical therapies for tissue repair, and its news flow reflects this specialization. Company announcements frequently highlight clinical progress for its late-stage investigational product EscharEx®, including updates on the global VALUE Phase III trial in venous leg ulcers and planned studies in diabetic foot ulcers and pressure ulcers. Investors and healthcare professionals can follow how these trials evolve, along with peer-reviewed publications that analyze wound bed preparation and healing outcomes.
News about MediWound also covers the commercial and clinical use of its FDA-approved biologic NexoBrid®, indicated for enzymatic removal of eschar in thermal burns. Recent releases have described new clinical data on NexoBrid in traumatic tattoos from abrasion and blast injuries, as well as its role in scientific presentations at major burn congresses. Regulatory milestones, such as marketing approval in Australia and expansion to 45 countries, feature prominently in the company’s updates.
Operational and financial developments are another key theme in MDWD news. MediWound reports on expansion and commissioning of its GMP manufacturing facility in Yavne, Israel, designed to increase NexoBrid production capacity, and on BARDA- and U.S. Department of Defense-funded projects, including work on a room temperature-stable formulation. Quarterly and annual financial results, equity financings under shelf registration statements, and revenue guidance are detailed in regular press releases and associated conference calls.
For readers tracking MDWD, this news stream offers insight into clinical trial milestones, regulatory decisions, manufacturing readiness, government-supported programs, and financial performance. Bookmark this page to follow ongoing developments that shape MediWound’s burn and chronic wound therapy portfolio.
MediWound Ltd. (Nasdaq: MDWD) announced that it will present updated clinical data from its EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring in National Harbor, Maryland, from April 26-30, 2023. Key opinion leaders will discuss current wound debridement practices and findings from the clinical studies during oral presentations on April 29, 2023. Two posters will present safety and efficacy results, showcasing EscharEx as a promising enzymatic solution for chronic wounds. CEO Ofer Gonen expressed confidence in EscharEx's potential as a leading treatment in the wound care market given its positive outcomes. The emphasis on EscharEx aligns with MediWound's commitment to advancing enzymatic solutions for tissue repair, with a Phase III study expected to commence in Q4 2023, highlighting its competitive advantages in the market.
MediWound Ltd. (NASDAQ: MDWD) reported total revenues of $26.5 million for 2022, a growth from $23.8 million in 2021, despite a 44% decrease in product revenue due to reduced BARDA procurement. The FDA approved NexoBrid in December 2022, leading to a $7.5 million milestone payment from Vericel. Operating loss improved to $8.3 million, down from $11.2 million in 2021. Cash position reached $66 million, supporting operations through 2026. EscharEx is set to enter Phase III trials in 2023, while launches in Japan and India are anticipated mid-2023.
FAQ
What is the current stock price of Mediwound (MDWD)?
What is the market cap of Mediwound (MDWD)?
